Top

Published in:

01-03-2016 | Original Article

CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed

Authors: B. Detti, P. Bonomo, L. Masi, R. Doro, S. Cipressi, C. Iermano, I. Bonucci, D. Franceschini, L. Di Brina, M. Baki, G. Simontacchi, I. Meattini, M. Carini, S. Serni, G. Nicita, L. Livi

Published in: World Journal of Urology | Issue 3/2016

Abstract

Purpose

To report a clinical experience of stereotactic body radiation therapy (SBRT) for isolated recurrence in the prostatic bed from prostate cancer.

Materials and methods

Between November 2011 and November 2013, 16 patients were treated with SBRT for a macroscopic isolated recurrence of prostate cancer in the prostatic bed. All patients were initially treated with radical prostatectomy, and half of them also received radiotherapy. Two schedules of SBRT were used: 30 Gy in 5 fractions in previously irradiated patients, 35 Gy in five fractions in radiotherapy-naïve patients.

Results

At a median follow-up of 10 months (range 2–21 months), a significant biochemical response was found in all but one patient. At imaging evaluation, no local progression was noted: 10 patients showed partial response while four stable disease. At the moment of analysis, all 16 patients were alive. Seven of them experienced distant relapse, while nine maintained biochemical control, with no further therapy. Median time to relapse was 9.3 months (range 3–15.2 months). The treatment was well tolerated: One patient experienced G2 acute genitourinary and gastrointestinal toxicity.

Conclusions

Our experience shows that SBRT with CyberKnife for isolated nodal relapse is a safe and well-tolerated treatment.

Hagan M, Zlotecki R, Medina C, Tercilla O, Rivera I, Wajsman Z (2004) Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 59(2):329–340CrossRefPubMed

Macdonald OK, Schild SE, Vora SA et al (2004) Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 58(5):1530–1535CrossRefPubMed

Anscher MS (2004) Salvage radiotherapy for recurrent prostate cancer: the earlier the better. JAMA 291(11):1380–1382CrossRefPubMed

Tomita N, Kodaira T, Furutani K et al (2009) Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy. J Cancer Res Clin Oncol 135(11):1561–1567CrossRefPubMed

Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing and castration-resistant prostate cancer. Eur Urol 59(4):572–583

Niibe Y, Chang JY (2012) Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med 2012:261096PubMedCentralCrossRefPubMed

Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M (2012) Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 17(8):1100–1107PubMedCentralCrossRefPubMed

Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164:101–105CrossRefPubMed

Chun FK, Graefen M, Zacharias M et al (2005) Anatomic radical retropubic prostatectomy long-term recurrence-free survival rates for localized prostate cancer. World J Urol 24:273–280CrossRef

10.

Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term biochemical disease free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 28:555–565CrossRefPubMed

11.

Bianco FJ Jr, Scardino PT, Eastham JA (2005) Radical prostatectomy: long term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 66:83–94CrossRefPubMed

12.

Trabulsi EJ, Valicenti RK, Hanlon AL et al (2008) A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 72:1298–1302PubMedCentralCrossRefPubMed

13.

Geinitz H, Riegel MG, Thamm R et al (2012) Outcome after conformal salvage radiotherapy in patients with rising prostate specific antigen levels after radical prostatectomy. Int J Radiat Oncol Biol Phys 82:1930–1937CrossRefPubMed

14.

Smith DP, King MT, Egger S et al (2009) Quality of life three years after diagnosis of localized prostate cancer: population based cohort study. BMJ 339:b4817PubMedCentralCrossRefPubMed

15.

Tsujimura A (2013) Role of androgen in the elderly. Problems of androgen deprivation therapy. Clin Calcium 23(8):1185–1190PubMed

16.

Hamberg P, Verhagen PC, de Wit R (2008) When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 44:1193–1197CrossRefPubMed

17.

Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8):563–572CrossRefPubMed

18.

Kal HB, Van Gellekom MP (2003) How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 57:1116–1121CrossRefPubMed

19.

Wang JZ, Li XA, Yu CX, DiBiase SJ (2003) The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? Int J Radiat Oncol Biol Phys 57:1101–1108CrossRefPubMed

20.

Jereczec-Fossa BA, Beltramo G, Fariselli L et al (2012) Robotic image-guided stereotactic radiotherapy for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82(2):889–897

21.

Catton C, Gospodarowicz M, Warde P et al (2001) Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 59:51–60CrossRefPubMed

22.

Stephenson AJ, Shariat S, Zelefsky M et al (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291:1325–1332CrossRefPubMed

23.

Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, Biagioli MC (2014) High-dose-rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy. Brachytherapy 13(2):123–127

24.

Gomez-Veiga F, Mariño A, Alvarez L, Rodriguez I, Fernandez C, Pertega S, Candal A (2012) Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. BJU Int 109(Suppl 1):17–21CrossRefPubMed

25.

Jung C, Cookson MS, Chang SS, Smith JA Jr, Dietrich MS, Teng M (2007) Toxicity following high-dose salvage radiotherapy after radical prostatectomy. BJU Int 99(3):529–533CrossRefPubMed

Title: CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed
Authors: B. Detti
P. Bonomo
L. Masi
R. Doro
S. Cipressi
C. Iermano
I. Bonucci
D. Franceschini
L. Di Brina
M. Baki
G. Simontacchi
I. Meattini
M. Carini
S. Serni
G. Nicita
L. Livi
Publication date: 01-03-2016
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 3/2016
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-015-1613-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed

Abstract

Purpose

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2016

Personalized 3D printed model of kidney and tumor anatomy: a useful tool for patient education

Mortality and flexible ureteroscopy: analysis of six cases

Robotic-assisted kidney transplantation: our first case

Diagnostic value of serum procalcitonin for acute pyelonephritis in infants and children with urinary tract infections: an updated meta-analysis

Prostatitis, other genitourinary infections and prostate cancer: results from a population-based case–control study

Comparison of renal function detriments after local tumor ablation or partial nephrectomy for renal cell carcinoma